Indinavir Anhydrous

Summary

Indinavir Anhydrous (CHEMBL115) is an approved small-molecule HIV protease inhibitor.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Chemistry: 613.8 Da · C36H47N5O4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL115
Name	Indinavir Anhydrous
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	5362440
ChEBI	CHEBI:44032
Molecular formula	C36H47N5O4
Molecular weight	613.8
InChIKey	CBVCZFGXHXORBI-PXQQMZJSSA-N

SMILES: CC(C)(C)NC(=O)[C@@H]1CN(CCN1C[C@H](C[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H]3[C@@H](CC4=CC=CC=C34)O)O)CC5=CN=CC=C5

IUPAC name: (2S)-1-[(2S,4R)-4-benzyl-2-hydroxy-5-[[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]amino]-5-oxopentyl]-N-tert-butyl-4-(pyridin-3-ylmethyl)piperazine-2-carboxamide

Pharmacological roles (ChEBI): HIV protease inhibitor.

Also known as: Indinavir anhydrous, INDINAVIR ANHYDROUS

Parent form; salt/anhydrous children: CHEMBL1735, CHEMBL5483011

Patent coverage: 11,061 distinct patent families (44,453 SureChEMBL compound mentions), from 3 matched compound structure(s). One matched structure accounts for 43,790 (99%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline, but PharmGKB curates 3 clinical and 6 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).